Avtor/Urednik		Mali, P; Jazbec, J
Naslov		Preživetje otrok in mladostnikov z akutno levkemijo v Sloveniji v obdobju 1990-1999
Prevedeni naslov		Survival of children and adolescents with acute leukaemia in Slovenia from 1990-1999
Tip		članek
Vir		Slov Pediatr
Vol. in št.		Letnik 9, št. 2-3
Leto izdaje		2002
Obseg		str. 86-9
Jezik		slo
Abstrakt		Treatment of acute leukaemia, one of the most common malignancies in children, has to be based on the relative risk of relapse. The purpose of this retrospective study of 154 patients with acute leukaemia treated in the Unit for oncology and haematology was to evaluate the outcome of treatment during the period from 1990 - 1999. For further analysis, only 109 patients with ALL, who had started chemotherapy 6 years earlier were included, as it is known that relapses after this period are rare. Overall, the 6-year survival for this group was 74%, while EFS was 75%. The two-year EFS in AML patients was 50.7%, while the overall survival was 33%. Treatment results could be compared with published results from BFM group, whose treatment protocols were used for our patients. Children with AML still have lower survival rates, mostly due to relapses and treatment-related complications.
Izvleček		Zdravljenje levkemije, najpogostejše rakave bolezni pri otroku, se prilagaja stopnji tveganja za ponovitev bolezni pri bolniku. Namen retrospektivne študije 154 bolnikov, ki so se v obdobju med 1990 - 1999 zdravili v Službi za onkologijo in hematologijo zaradi akutne levkemije, je bil oceniti uspešnost zdravljenja. V nadaljnjo analizo smo vključili 109 bolnikov z ALL, pri katerih je od začetka zdravljenja preteklo 6 let, ko je ponovitev bolezni redka. Celokupno več kot 6-letno preživetje skupine je bilo 74%, obdobje brez bolezni (OBB) pa 75%. Pri 21 bolnikih z AML je 2-letni OBB 50,7%, celokupno preživetje je 33%. Uspehi zdravljenja ALL pri nas so primerljivi z rezultati študije BFM, katere shemo zdravljenja smo uporabili. Bolniki z AML še vedno ostajajo bolniki s slabo prognozo tako glede ponovitve bolezni, kot tudi zaradi številnih zapletov ob zdravljenju.
Deskriptorji		LEUKEMIA, LYMPHOCYTIC, ACUTE LEUKEMIA, MYELOCYTIC, ACUTE CHILD ADOLESCENCE SURVIVAL ANALYSIS